TransVoyant, Inc.

TransVoyant, Inc. delivers advanced AI-driven supply chain solutions that enhance decision-making processes for businesses across various industries, optimizing operational efficiency and risk management. TransVoyant, Inc. is focused on providing an AI-driven supply chain flow and behavior platform.

Founded in 2012 in Alexandria, US, the company has executed a total of 5 deals, with its latest funding round being a Series C in December 2022, raising USD 2. 95 million from investors including Merck Global Health Innovation Fund and P74 Ventures. Current valuation stands at USD 54. 63 mn.

The company is led by CEO Dennis Groseclose. TransVoyant specializes in an AI-driven supply chain flow and behavior platform designed to enhance decision-making across global business operations. Their core offerings enable organizations to visualize and analyze both historical and real-time data pertaining to flow, behavior, risk, and opportunities within their supply chains. By providing tools for continuous innovation and predictive analysis, TransVoyant assists businesses in optimizing processes, mitigating risks, and capitalizing on emerging opportunities in their value chains.

Their solutions target industries such as healthcare, logistics, and manufacturing, serving a diverse client base that includes notable organizations like Merck and McKesson. The company operates primarily in North America, Europe, and Asia, ensuring that its intelligent platform caters to global enterprises navigating complex supply chain dynamics. TransVoyant's revenue model is centered around a subscription-based service, enabling organizations to access its AI-driven platform for ongoing operational insights and analytics. Clients engage with the company through tiered subscription plans, which may include additional fees for advanced features or enhanced data services.

The transactions typically involve long-term contracts that facilitate continuous data integration and analytics support, fostering a collaborative relationship between TransVoyant and its clients. Notable offerings within this model include their flagship Continuous Decision Intelligence™ platform, which provides comprehensive insights into supply chain performance and predictive capabilities. While specific pricing details for these subscription plans are not disclosed, the structure supports a steady revenue stream derived from ongoing client engagements. In December 2022, TransVoyant, Inc.

raised USD 2. 95 million in Series C funding, co-led by new investors Merck Global Health Innovation Fund and P74 Ventures. The funding will be used to scale operations, reach new customers, and expand the platform's use cases. The company plans to target new geographic regions and enhance their product offerings, although specific new products and timelines for expansion have not been disclosed.